LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Market Closed 01-30 16:08:04

13.700

-1.100

-7.43%

High14.800	Low13.650	Vol2.60M
Open14.800	D1 Closing14.800	Amplitude7.77%
Mkt Cap6.11B	Tradable Cap6.11B	Total Shares446.00M
T/O36.34M	T/O Rate0.58%	Tradable Shares446.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":13.7,"timestamp":1769760484002,"preClose":14.8,"halted":0,"volume":2601000,"delay":0,"changeRate":-0.07432432432432441,"floatShares":446000000,"shares":446000000,"eps":-0.711066,"marketStatus":"Market Closed","change":-1.1,"latestTime":"01-30 16:08:04","open":14.8,"high":14.8,"low":13.65,"amount":36335815,"amplitude":0.077703,"askPrice":13.76,"askSize":3000,"bidPrice":13.7,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-0.59,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769995800000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":14.8,"openAndCloseTimeList":[[1769736600000,1769745600000],[1769749200000,1769760000000]],"volumeRatio":0.6616468673126175,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2606925300","title":"An Insider At Laekna Lowered Their Holding Recently","url":"https://stock-news.laohu8.com/highlight/detail?id=2606925300","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606925300?lang=en_us&edition=fundamental","pubTime":"2026-01-25 08:09","pubTimestamp":1769299773,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net sellers in Laekna, Inc.'s ( HKG:2105 ) during the past 12 months. That is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/an-insider-at-laekna-lowered-their-holding-recently","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/an-insider-at-laekna-lowered-their-holding-recently","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1179784108","title":"LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1179784108","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179784108?lang=en_us&edition=fundamental","pubTime":"2026-01-16 13:44","pubTimestamp":1768542288,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million. The company announced that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1132319443","title":"LAEKNA-B (02105) Rises Nearly 7% as FDA Accepts IND Application for New Drug LAE118","url":"https://stock-news.laohu8.com/highlight/detail?id=1132319443","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132319443?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:38","pubTimestamp":1768354704,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) rose nearly 7% during the morning session. At the time of writing, the stock was up 5.88%, trading at HK$14.23 with a turnover of HK$9.34 million. On January 14, LAIKE Medicine...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1152771100","title":"LAEKNA-B (02105): US FDA Accepts LAE118 New Drug Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1152771100","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152771100?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:16","pubTimestamp":1768349796,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118. LAE118 is a novel, pan-mutant selective PI3Kα...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2603599206","title":"FDA Accepts Investigational New Drug Application for Laekna LAE118","url":"https://stock-news.laohu8.com/highlight/detail?id=2603599206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603599206?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:11","pubTimestamp":1768349482,"startTime":"0","endTime":"0","summary":"Laekna Inc. announced that the U.S. Food and Drug Administration  has accepted its Investigational New Drug  application for LAE118, a novel PI3Kα pan-mutant selective inhibitor intended for the treatment of patients with PIK3CA-mutant solid tumors. The company stated it will work closely with regulatory authorities to advance LAE118 into clinical studies. Laekna also cautioned that there is no guarantee the drug will ultimately be successfully developed and commercialized. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2KzY99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2595742497","title":"Laekna Doses Subject in LAE103 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2595742497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595742497?lang=en_us&edition=fundamental","pubTime":"2025-12-31 10:50","pubTimestamp":1767149457,"startTime":"0","endTime":"0","summary":"Laekna  said it had dosed the first subject in the phase 1 clinical trial of LAE103, according to  a Hong Kong bourse filing Wednesday.The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103 in overweight or obese subjects.Topline data from the SAD study is expected in the third quarter of 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1100137130","title":"LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103","url":"https://stock-news.laohu8.com/highlight/detail?id=1100137130","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100137130?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:40","pubTimestamp":1767141623,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia. As...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2595745146","title":"Laekna Inc. Doses First Subject in Phase I Trial of LAE103 for Obesity and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745146","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595745146?lang=en_us&edition=fundamental","pubTime":"2025-12-31 08:11","pubTimestamp":1767139887,"startTime":"0","endTime":"0","summary":"Laekna Inc. has announced the commencement of a Phase I single ascending dose  clinical study for LAE103, an internally discovered monoclonal antibody targeting ActRIIB. The study is being conducted in Australia and is designed as a randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE103 in healthy overweight or obese participants. According to the company, topline data from this study are expected to be available in the third quarter of 2026. No study results have been presented at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDLBsj03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2593717289","title":"Laekna Doses First Patinet in Weight Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2593717289","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593717289?lang=en_us&edition=fundamental","pubTime":"2025-12-22 09:35","pubTimestamp":1766367342,"startTime":"0","endTime":"0","summary":"Laekna (HKG:2105) dosed the first subject in the phase 1 study of AE102 in China for the treatment of obesity, according to a Hong Kong bourse filing Monday.The firm plans to enroll 60 subjects in the trial for a period of six months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1148177036","title":"LAEKNA-B (02105): First Patient Dosed in Phase I Multiple-Dose Expansion Study of LAE102 for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1148177036","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148177036?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:26","pubTimestamp":1766363171,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the group has initiated patient enrollment for a Phase I multiple-dose expansion study of LAE102 targeting obesity treatment in China and has completed dosing the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2593179225","title":"Laekna Inc. Begins Phase I Multiple Dose Study of LAE102 for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2593179225","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593179225?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:15","pubTimestamp":1766362549,"startTime":"0","endTime":"0","summary":"Laekna Inc. has announced the commencement of a Phase I multiple dose expansion study of LAE102 for the treatment of obesity in China. The study is a randomized, double-blind, placebo-controlled trial involving 60 overweight or obese subjects, who will receive either LAE102 or placebo over a six-month period. The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102. This trial follows positive one-month results from an earlier multiple ascending dose  study. Results from the current study have not yet been presented and will be available in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via II","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL86mPw4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2591993396","title":"Laekna Completes Patient Enrollment In LAE002 Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591993396","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591993396?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:32","pubTimestamp":1765765937,"startTime":"0","endTime":"0","summary":"Laekna  completed patient enrollment in the phase 3 clinical trial of LAE002 to treat breast cancer, according to a Hong Kong bourse filing Monday.The late-stage trial, called AFFIRM-205, will study LAE002 in combination with fulvestrant. Topline data is expected in the first half of 2026, followed by a new drug application with Chinese regulators later in the year, the firm said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1132712108","title":"LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1132712108","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132712108?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:20","pubTimestamp":1765758016,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK1161","III","BK4203","02105","HR","BK4225"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","AZN.UK","LU0345777147.USD","LU1035775433.USD","LU0306806265.USD","LU1323610961.USD","SG9999014906.USD","ALT","LU1003077747.HKD","SG9999015986.USD","SG9999002224.SGD","IE00BN8TJ469.HKD","GPCR","LU1989771016.USD","LU0256863902.USD","LU0211328371.USD","03692","MRK","VKTX","03933","SG9999013999.USD","LU0499090636.EUR","IE00BJJMRX11.SGD","LU0130517989.USD","IE00BJLML261.HKD","02105","IE0005OL40V9.USD","LU2106854487.HKD","LU0106261372.USD","IE0002141913.USD","SGXZ99366536.SGD","BK0188","BK0028","IE00BK4W5M84.HKD","SRRK","BK4566","LU0964806797.USD","LU1989772840.SGD","600196","OPK","LLY","BK0187","MTSR","IE00B4JS1V06.HKD","LU0823434583.USD","00656","AMGN","LU1061106388.HKD","03165"],"gpt_icon":1},{"id":"1135675546","title":"LAEKNA-B (02105): Xie Ling and Zhou Jian Appointed as Members of Nomination and Corporate Governance Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1135675546","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135675546?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:06","pubTimestamp":1765533995,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that, effective December 12, 2025, Executive Director Ms. Xie Ling and Independent Non-Executive Director Mr. Zhou Jian have been appointed as members of the company's Nomination and Corporate Governance Committee.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2590937577","title":"Laekna Inc. Files Director List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590937577?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:03","pubTimestamp":1765533789,"startTime":"0","endTime":"0","summary":"Laekna Inc., a biopharmaceutical company listed on the Hong Kong Stock Exchange , has filed an updated list of directors and their roles. The Board is chaired by Dr. LU Chris Xiangyang, who also serves as Chief Executive Officer. Other executive directors include Ms. XIE Ling and Dr. GU Xiang-Ju Justin. The non-executive directors are Dr. WANG David Guowei and Mr. SUN Yuan. Independent non-executive directors comprise Dr. YIN Xudong, Dr. LI Min, and Mr. ZHOU Jian. Committee memberships are as follows: Dr. LU Chris Xiangyang chairs the Nomination and Corporate Governance Committee, with Ms. XIE Ling, Dr. LI Min, and Mr. ZHOU Jian as members. Mr. ZHOU Jian chairs the Audit Committee, joined by Dr. WANG David Guowei and Dr. LI Min as members. The Remuneration Committee is chaired by Dr. YIN Xudong, with Ms. XIE Ling and Mr. ZHOU Jian serving as members.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3blG8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2590157764","title":"Laekna Inc. Appoints Xie Ling and Zhou Jian to Nomination and Corporate Governance Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2590157764","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590157764?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:01","pubTimestamp":1765533689,"startTime":"0","endTime":"0","summary":"Laekna Inc. has announced changes to its Nomination and Corporate Governance Committee. Ms. XIE Ling and Mr. ZHOU Jian have been appointed as new members, joining Dr. LU Chris Xiangyang, Dr. YIN Xudong, and Dr. LI Min. Dr. LU Chris Xiangyang will serve as the committee's chairperson.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6LDJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1130982436","title":"HK Stock Movement | LAEKNA-B (02105) Rises Over 5% in Early Trading, LAE002 Expected to Submit NDA in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1130982436","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130982436?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:08","pubTimestamp":1764814097,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) surged more than 5% in early trading, reaching HK$16.9 with a turnover of HK$28.7 million. The company recently signed an exclusive agreement with Qilu Pharmaceutical, granting Qilu...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03896","BK1552","IE00BYV24P56.USD","LU1807302812.USD","02858","LU0143863784.USD","LU0449515922.USD","LU1023057109.AUD","SG9999001069.SGD","LU0605514214.HKD","LU0140636845.USD","BK1571","BK1197","LU2476274308.USD","01585","02150","IE00B031J352.USD","LU0823437842.USD","LU2543165471.USD","IE00B0169L03.USD","01530","LU1497733557.USD","BK1186","BK1613","01448","BK1595","BK1163","BK1539","02392","09911","LU1152091168.USD","82020","BK1151","03836","IE0034224299.USD","02565","02567","BK1577","03681","LU0072913022.USD","BK1148","BK1610","02057","LU0348767384.USD","LU2399975544.HKD","LU0211977185.USD","LU0049112450.USD","00300","09639","IE00B8HQ1Z84.USD","02419","LU1508157978.USD","09985","09927","03145","02190","02382","02315","80992","BK1597","LU0231483743.USD","LU0791590937.USD","BK1189","03998","LU2097828714.EUR","LU2039709279.SGD","BYDDY","BK1100","BK1512","03677","00999","09878","01333","02256","LU1267930227.SGD","09996","BK1143","LU1481107354.HKD","BK1526","SG9999000475.SGD","BK1137","IE00BPRC5H50.USD","01070","HK0000252152.HKD","LU0516423091.SGD","LU0348783233.USD","LU0823038988.USD","06609","LU2097828631.EUR","BK1521","06060","HYDD.SI","LU1880383366.USD","03650","LU2097828557.USD","06919","LU0456846285.SGD","LU1303224171.USD","SG9999002828.SGD","00020","IE0031814852.USD","01471","LU0067412154.USD","LU0082770016.SGD","LU0269904917.USD","LU1188198961.HKD","01378","06608","BK1171","LU0287142896.SGD","00875","LU0048575426.USD","LU0259732245.USD","HK0000165453.HKD","02650","LU1366334651.USD","LU0164939612.USD","01969","01651","02020","BK1239","02100","09660","LU0329678337.USD","LU1956131251.USD","LU0289739343.SGD","BK1160","LU0149721374.USD","01519","LU1917777945.USD","BK1131","LU2506951792.HKD","01952","LU0791591158.USD","BK1179","01809","02598","LU0640798160.USD","09880","BK1136","BK1139","BK1598","BK1589","SG9999002463.SGD","BK1194","LU2153591404.USD","LU0823397285.USD","BK1530","LU0327786744.USD","LU2328871848.SGD","BK1225","LU0254981946.USD","BK1141","LU0011963245.USD","LU0819121731.USD","LU2125910500.SGD","LU0593848301.USD","BK1114","BK1209","LU1226287792.SGD","SG9999002950.SGD","LU1961090484.USD","BK1585","BK1161","02105","06138","SG9999003461.SGD","LU0499858438.USD","01681","BK1619","LU0164865239.USD","BK1500","BK1502","00302","BK1548","LU1328615791.USD","09992","IE0032431581.USD","LU1008478684.HKD","SG9999001903.USD","LU1770036033.HKD","LU0823414478.USD","BK1596","BK1604","IE00B5MMRT66.SGD","01318","02228","BK1190","BK1594","LU0264606111.USD","BK1214","06058","LU0650527681.SGD","LU1868838027.USD","00451","IE00BZ08YS42.EUR","LU0261950470.USD","09636","LU1235295612.USD","002594","LU0455707207.USD","BK1127","01833","01177","LU1211504680.USD","BK1207","02552","BK1247","LU0762540952.USD","BK1607","LU1166156734.SGD","SG9999014674.SGD","BK1110","06657","IE0009570106.USD","BK1167","BK1559","LU0819123356.HKD","LU1960683339.HKD","00267","LU1282649810.SGD","01877","LU1880383440.USD","HK0000500386.USD","LU0828237510.HKD","BK1617","SG9999002562.SGD","LU1939255532.USD","86618","LU0871576103.HKD","02886","BK1515","06090","BK1253","LU0214875030.USD","SG9999001226.SGD","LU0348825331.USD","03800","LU0823426480.USD","LU1039395188.USD","LU0588546209.SGD","LU0868486357.SGD","LU0469268626.HKD","BK1142","BK1582","BK1183","LU0561508036.HKD","01211","LU0261950983.USD","LU0417516902.SGD","SG9999006514.SGD","01735","LU0326950275.SGD","IE00BMCWC346.EUR","02279","LU2249611893.SGD","02696","SG9999006597.SGD","LU0541502299.USD","BK1516","LU1226287875.USD","SGXZ86797644.SGD","LU3063872942.SGD","IE0003795394.USD","BK1132","01783","BK1588","BK1117","02096","BK1258","LU0261947096.USD","BK1229","LU0463099449.HKD","LU2360107325.USD","LU1522347837.USD","LU0228659784.USD","LU0107464264.USD","LU2506952253.HKD","LU0702159699.USD","LU1794554557.SGD","00798","01384","LU0359201612.USD","BK1168","LU0509642566.USD","LU1861219969.SGD","06683","02590","BK1119","LU0449509016.USD","LU0572944931.SGD","06100","06086","BK1144","LU0865486749.SGD","LU2008162690.USD","LU1226288253.USD","BK1579","LU2106854487.HKD","02551","BK1228","LU0244354667.USD","BK1522","BK1193","IE00BQXX3C00.GBP","00382","LU0175139822.USD","LU1102505762.USD","BK1198","BK1184","LU1868837565.USD","IE00BQXX3F31.USD","01117","01739","09699","02400","01939","00305","LU0307460666.USD","LU0289960550.SGD","LU0320764599.SGD","BK1128","LU0345776255.USD","LU1282649067.USD","LU1861214812.USD","LU0229945570.USD","02525","LU0274383008.USD","BK1531","02616","LU1251922891.USD","LU0384037296.USD","02013","BK1104","LNVGY","LU1046422090.SGD","BK1111","LU0531971595.HKD","02276","BK1215","06988","00960","HK0000320223.HKD","BK1592","02142","BK1504","LU0708995583.HKD","ANPDY","LU1242518931.SGD","LU1770034418.SGD","BK1230","LU0634319403.HKD","SG9999015945.SGD","06913","06821","HK0000320264.USD","01911","BK1593","LU1868837722.USD","00656","00826","BK1542","LU0072462343.USD","06069","00460","BK1586","IE00BVYPNP33.GBP","02506","LU0531970944.HKD","LU2357125470.USD","BK1164","BK1564","LU0165289439.USD","01520","BK1566","BK1590","BK1126","BK1220","06862","02453","LU2424517915.HKD","BK1191","00992","BK1221","02595","BK1556","03680","09690","LU0048580855.USD","LU2153592121.USD","LU0251144936.SGD","SG9999004220.SGD","BK1219","SG9999015986.USD","02460","02511","02587","LU0370786039.SGD","09678","09923","BK1518","LU0329678170.USD","LU1808992512.USD","BK1608","03738","06963","BK1235","LU0516423174.USD","09961","LU0541501648.USD","LU0164880469.USD","LU0488056044.USD","BK1528","BK1557","BK1524","LU1969619763.USD","LU1328277881.USD","03709","00017","LU0516422952.EUR","LU0540923850.HKD","SG9999015978.USD","LU0823039010.USD","LU1993786604.SGD","LU0052750758.USD","BK1509","06613","LU0417516571.SGD","LU2177674079.SGD","IE00B0JY6N72.USD","LU0345775950.USD","02469","09959","BK1554","02298","BK1544","LU1675838814.USD","09990","80020","LU0051755006.USD","LU1951186391.HKD","BK1216","BK1125","00861","02018","LU0499858602.USD","IE0003851619.USD","LU1224709979.USD","BK1150","BK1200","BK1549","LU1048588211.SGD","BK1170","06996","00136","82331","HK0000306701.USD","LU0054450605.USD","LU0164872284.USD","IE00BD6J9T35.USD","02627","BK1154","LU1115378108.SGD","00666","00855","LU0348784397.USD","LU0348805143.USD","81211","IE00BZ08YR35.GBP","IE0008368742.USD","IE00BGHQDM52.EUR","BK1553","BK1575","00003","LU1634259391.SGD","BK1587","BK1240","BK1550","LU0594300179.USD","LU0314109678.HKD","02451","BK1578","BK1169","LU0431992006.USD","LU0143863198.USD","BK1540","00363","02498","LU0082770016.USD","LU0417516738.SGD","LU1981816686.USD","02533","06633","BK1224","BK1222","01880","09890","LU1242518857.USD","LU1497734951.SGD","LU2348773727.SGD","BK1605","02145","LU0880133367.SGD","06160","BK1583","02177","LU0289961442.SGD","SG9999001093.SGD","IE00B543WZ88.USD","HK0000306685.HKD","IE00B031HY20.USD","02155","03939","01440","BK1616","LU0511384066.AUD","02158","01818","02509","LU0128525689.USD","LU2242644610.SGD","LU0348735423.USD","IE00BZ08YT58.USD","09919","LU1831875114.USD","BK1257","BK1600","BK1606","LU0516422440.USD","SG9999000418.SGD","01640","LU1720050803.USD","02420","BK1096","BK1155","LU0456827905.SGD","IE00BQXX3D17.EUR","09955","BK1124","09877","01600","02436","LU0084288322.USD","BK1519","LU1974910355.USD","02380","06186","SGXZ62798434.SGD","BK1591","BK1195","BK1574","LU2023250504.SGD","LU1497733631.SGD","BK1134","IE00B8L5B284.USD","02273","03658","BK1140","LU0502904849.HKD","LU2488822045.USD","LU2298064838.USD","LU0501845795.SGD","LU0359201885.HKD","LU0588545730.USD","02121","01119","02331","LU0505663152.USD","LU0737861699.HKD","LU2294711713.HKD","LU1634259557.SGD","BK1158","BK1116","LU1102505929.USD","LU2045819591.USD","00512","00884","BK1555","BK1233","BK1609","01276","BK1227","SG9999004311.SGD","02556","SG9999000459.SGD","00867","00135","LU0611395673.USD","LU0588545904.SGD","01907","LU0516422366.SGD","02250","LU0173614495.USD","BK1618","01164","06168","BK1109","LU0823426308.USD","BK1541","BK1520","LU0588545490.SGD","02889","BK1175","BK1212","BK1527","LU0572939691.SGD","LU2238339852.HKD","01458","LU0359202008.SGD","LU0039217434.USD","02197","LU1226288170.HKD","IE00BVYPNQ40.USD","02171","LU1152091754.HKD","LU1719994722.HKD","02488","02431","LU0737861772.HKD","LU0315179316.USD","01762","LU0310800965.SGD","01405","LU0823414551.USD","BK1523","LU1813983027.USD","SG9999001051.SGD","00777","LU0620787316.HKD","IE00B29SXG58.USD","00699","LU0594300419.USD","06618","02157","HK0000252160.HKD","02670","LU0348766576.USD","LU2663582299.SGD","BK1560","IE00BGV7N243.SGD","SG9999015952.SGD","02268","03396","BK1237","BK1178","LU1366334578.USD","02167","06677","IE0008369823.USD","LU0348827113.USD","09860","02629","LU2348774022.SGD","LU2097828805.USD","LU2097828474.EUR","LU0856984785.SGD","LU0543330566.HKD","01093","LU0043850808.USD","BK1188","LU0979878070.USD","BK1615","LU0251143458.SGD","LU0315178854.USD","LNNGY","LU0048597586.USD","BK1095","BK1147","LU0823397103.USD","SG9999011746.SGD","LU0831093199.SGD","LU2449936058.SGD","09956","06855","LU1226287529.USD","SGXZ90724238.SGD","LU2476274720.SGD","01773","LU0054237671.USD","LU0828238088.HKD","LU0052756011.USD","LU2778985437.USD","09926","02411","00384","LU0572940350.SGD","LU2460026573.USD"],"gpt_icon":1},{"id":"1172872567","title":"Laekna, Inc. (02105) Reports Unchanged Share Structure in November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1172872567","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172872567?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:25","pubTimestamp":1764753950,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (02105) published its monthly return detailing the share capital structure for the period ended 30 November 2025. The authorized share capital remained at 5,000,000,000 ordinary shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.1405},{"period":"1month","weight":0.0096},{"period":"3month","weight":0.165},{"period":"6month","weight":-0.218},{"period":"1year","weight":0.4811},{"period":"ytd","weight":0.0096}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}